Anti-Mouse γ/δ (TCR) – Purified in vivo GOLD™ Functional Grade

Unknown

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

The anti-mouse γ/δ T-cell receptor antibody reacts with all mouse TCR γ/δ heterodimers.

γδ TCR expression is observed on a subset of cells in the thymus, intestinal epithelium, skin, liver, peripheral lymphoid tissues, and peritoneum. The γδ TCR is involved in the antigen recognition of some bacterial or tumor-associated antigens presented by MHC class I.

The T cell receptor or TCR is a molecule found on the surface of T lymphocytes that is responsible for recognizing antigens bound to major histocompatibility complex (MHC) molecules. It is a heterodimer consisting of an α and β chain in 95% of T cells, while 5% of T cells have TCRs consisting of γ and δ chains. Engagement of the TCR with antigen and MHC results in activation of its T lymphocyte through a series of biochemical events mediated by associated enzymes, co-receptors and specialized accessory molecules.

Some bacterial or tumor antigens bound MHC class I

Antigen recognition

1.) Bluestone, J. A et al. (1991) Immunol. Rev. 120:5-33 Journal Link
2.) Hiromatsu K et al. (1992) J. Exp. Med. 175 (1):49-56 Journal Link
3.) van der Heyde HC et al. (1995) J. Immunol. 154 (8): 3985-3990 Journal Link
4.) Pollinger B et al. (2011) J. Immunol. 186 (4):2602-12 Journal Link